Cancer gene assays from FFPE

• EGFR assays from FFPE
  8 December 2011

  Assays
  EGFR CISH from FFPE (#18382350#)
  References
  Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). Fischer I, de la Cruz C, Rivera AL, Aldape K. Diagn Mol Pathol. 2008 Dec;17(4):227-30. PMID: #18382350#

• EGFR ISH from FFPE
  8 December 2011

  EGFR CISH from FFPE

• HER2 qRT-PCR from FFPE
  8 December 2011

  The availability of drugs targeting the EGFR/HER/erbB signaling pathway has created a need for diagnostics that accurately predict treatment responses.
  The selection of patients with HER2-positive breast cancer for treatment with trastuzumab is based on the measurement of HER2 protein expression by immunohistochemistry, or the presence of HER2 gene amplification by fluorescence in situ hybridization (FISH).
  Real time PCR is a reliable and cost-effective method for the assessment of ERBB2 (...)

• fusion transcript detection from FFPE
  8 December 2011

  Fusion transcripts
  ASPL-TFE3 (#18382356#) alveolar soft part sarcoma
  FUS-CREB3L2 low-grade fibromyxoid sarcoma (#18382348#)
  References
  DNA-based polymerase chain reaction for detecting FUS-CREB3L2 in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Matsuyama A, Hisaoka M, Shimajiri S, Hashimoto H. Diagn Mol Pathol. 2008 Dec;17(4):237-40. PMID: #18382348#
  Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and (...)

• DHPLC for the detection of MSI
  8 December 2011

  Denaturing high performance liquid chromatography for the detection of microsatellite instability

• JAK2 assays from FFPE
  7 December 2011

  References
  A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients. Burjanivova T, Marcinek J, Lasabova Z, Minarik G, Szepe P, Balharek T, Vanochova A, Polacek H, Plank L. Diagn Mol Pathol. 2009 Jun;18(2):108-11. PMID: #19430293#

• HER2 assays from FFPE
  7 December 2011

  ERBB2 assays from FFPE

• Oncogenetics anomalies from saliva
  7 December 2011

  Non-invasive high-throughput multiplex ligation-dependent probe amplification identified discrete gene signatures that differentiated HNSCC patients from normal controls providing proof-of-concept for noninvasive HNSCC detection. (#19430297#)
  References
  Noninvasive molecular detection of head and neck squamous cell carcinoma: an exploratory analysis. Sethi S, Benninger MS, Lu M, Havard S, Worsham MJ. Diagn Mol Pathol. 2009 Jun;18(2):81-7. PMID: #19430297# (...)

• KRAS assays from FFPE
  7 December 2011

  Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an important cell-signaling pathway promoting tumorigenesis, and are increasingly recognized as determinants of response to targeted cancer therapies.
  The frequency of KRAS mutations is about 32%, with G>A transitions at position 2 of codons 12 and 13 being most prevalent.
  References
  Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic (...)

• BRAF assays from FFPE
  7 December 2011

  Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an important cell-signaling pathway promoting tumorigenesis, and are increasingly recognized as determinants of response to targeted cancer therapies.
  The BRAF-V600E mutation accounts for most of the BRAF mutations in cancer, and KRAS mutations are predominantly encoded by nucleotide substitutions within codons 12 and 13.
  The BRAF V600E mutation is detected in about 13% of the colorectal cancers.
  The (...)

0 | 10